A Phase 2 interventional study of VELCADE and Rituximab in Diffuse Large B-Cell Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-01-13.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing bortezomib in Lymphoma, Large B-Cell, Diffuse — none open to participants now, none under way, none of them phase 3. Bortezomib · Lymphoma, Large B-Cell, Diffuse.
Among the 29 studies testing bortezomib in Lymphoma, Large B-Cell, Diffuse, this one is the 4th largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2010, is one of 13 in phase 2, and was the 18th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 357 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →None of the 29 studies testing bortezomib in Lymphoma, Large B-Cell, Diffuse is open now. The open studies under Lymphoma, Large B-Cell, Diffuse, anywhere →
Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 18 · Phase 3 1
First in 1999; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 164 is above the median of 45 across 1,499 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 35 across the 26 interventional studies. Of the 25 that completed or were terminated, 11 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
Takeda has 7 studies filed under Lymphoma, Large B-Cell, Diffuse — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing bortezomib in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, open-label, active-control, parallel-group, multicenter, multinational Phase 2 Study of the efficacy and safety of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients With Newly Diagnosed Non-Germinal Center B-Cell (non-GCB) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VR-CAP arm received rituximab 375 mg/m2 IV on Day 1, cyclophosphamide 750 mg/m2 IV on Day 1, doxorubicin 50 mg/m2 IV on Day 1, VELCADE 1.3 mg/m2 IV on Days 1, 4, 8, and 11, and prednisone 100 mg/m2 orally on Days 1 through 5 of each 21-day (3-week) cycle for up to 6 cycles.
Drug: VELCADE · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Prednisone
R-CHOP received rituximab 375 mg/m2IV on Day 1, cyclophosphamide 750 mg/m2 IV on Day 1, doxorubicin 50 mg/m2 IV on Day 1, vincristine 1.4 mg/m2 (maximum total of 2 mg) IV on Day 1, and prednisone 100 mg/m2 orally on Days 1 through 5 of each 21-day (3-week) cycle for up to 6 cycles.Prednisone
Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Prednisone · Drug: Vincristine
VELCADE intravenous on Days 1, 4, 8, and 11 of a 21 day (3 week) cycle for 6 cycles.
Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
Orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles
Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
Complete Response (CR) Rate
Complete response was evaluated by an Independent Radiology Review Committee using available computed tomography (CT) and positron emission tomography (PET) scans collected at Baseline, end of cycle 3, and end of cycle 6 (or end of treatment) based on the Revised Response Criteria for Malignant Lymphoma. 1. Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. 2. PET scan was negative. 3. The spleen and/or liver, if enlarged before therapy on the basis of physical examination or CT scan, was not palpable on physical examination and was considered normal size by imaging studies; all splenic and hepatic nodules related to lymphomas disappeared. 4. If bone marrow was involved before treatment, the infiltrate cleared on repeated bone marrow biopsy. 5. No new sites of disease were detected.
Time frame: 6 cycles
Overall Response Rate
Overall response = Complete Response (CR) + Partial Response (PR) Response was evaluated by an Independent Radiology Review Committee using available computed tomography (CT) and positron emission tomography (PET) scans collected at Baseline, end of cycle 3, and end of cycle 6 (or end of treatment) based on the Revised Response Criteria for Malignant Lymphoma. Complete Response: see primary endpoint Partial Response: At least a 50% decrease in the sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses.
Time frame: 6 cycles
Rate of Durable Response
Proportion of subjects who achieved a CR or PR with duration of at least 6 months. Duration of response (CR or PR) was calculated from the date of initial documentation of a response to the date of first documented evidence of disease progression or death due to disease progression. Response was evaluated by an Independent Radiology Review Committee using available computed tomography (CT) and positron emission tomography (PET) scans collected at Baseline, end of cycle 3, end of cycle 6 (or end of treatment) based on the Revised Response Criteria for Malignant Lymphoma.
Time frame: Median follow up approx. 12 months
Rate of Durable Complete Response
Proportion of subjects who achieved a CR with duration of at least 6 months
Time frame: Median follow up approx 12 months
Subsequent Anti-lymphoma Therapy Rate at 1-year
Kaplan-meier estimate of subsequent anti-lymphoma therapy at 1-year. Time to subsequent anti-lymphoma therapy was measured from the date of randomization to the start date of new treatment. Death due to disease progression prior to subsequent therapy was considered as an event. Otherwise, time to next anti-lymphoma treatment was censored at the date of death or the last date known to be alive.
Time frame: 1 year
Progression-free Survival (PFS)Rate at 1-year
Kaplan-meier estimate of progression-free survival at 1-year. Progression-free survival was defined as the interval between the date of randomization and the date of first documented evidence of disease progression or death.
Time frame: 1 year
Overall Survival Rate at 1-year
Kaplan-meier estimate of overall survival at 1-year measured from date of randomization.
Time frame: 1 year
Change in Fatigue and Patient Utility Scores
Time frame: 18-24 months
| Milestone | VR-CAP | R-CHOP |
|---|---|---|
| Started | 84 | 80 |
| Completed | 71 | 73 |
| Not completed | 13 | 7 |
| Withdrew: Adverse event | 6 | 2 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Death | 1 | 3 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Drug supply issue | 1 | 0 |
| Withdrew: Randomized and not treated | 2 | 1 |
Complete response was evaluated by an Independent Radiology Review Committee using available computed tomography (CT) and positron emission tomography (PET) scans collected at Baseline, end of cycle 3, and end of cycle 6 (or end of treatment) based on the Revised Response Criteria for Malignant Lymphoma. 1. Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. 2. PET scan was negative. 3. The spleen and/or liver, if enlarged before therapy on the basis of physical examination or CT scan, was not palpable on physical examination and was considered normal size by imaging studies; all splenic and hepatic nodules related to lymphomas disappeared. 4. If bone marrow was involved before treatment, the infiltrate cleared on repeated bone marrow biopsy. 5. No new sites of disease were detected.
| percentage of participants | VR-CAP | R-CHOP |
|---|---|---|
| Complete Response (CR) Rate | 64.5 (55.4 to 73.5) | 63.5 (54.3 to 72.7) |
Overall response = Complete Response (CR) + Partial Response (PR) Response was evaluated by an Independent Radiology Review Committee using available computed tomography (CT) and positron emission tomography (PET) scans collected at Baseline, end of cycle 3, and end of cycle 6 (or end of treatment) based on the Revised Response Criteria for Malignant Lymphoma. Complete Response: see primary endpoint Partial Response: At least a 50% decrease in the sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses.
| percentage of participants | VR-CAP | R-CHOP |
|---|---|---|
| Overall Response Rate | 93.4 (88.7 to 98.1) | 98.6 (96.4 to 100.0) |
Proportion of subjects who achieved a CR or PR with duration of at least 6 months. Duration of response (CR or PR) was calculated from the date of initial documentation of a response to the date of first documented evidence of disease progression or death due to disease progression. Response was evaluated by an Independent Radiology Review Committee using available computed tomography (CT) and positron emission tomography (PET) scans collected at Baseline, end of cycle 3, end of cycle 6 (or end of treatment) based on the Revised Response Criteria for Malignant Lymphoma.
| percentage of participants | VR-CAP | R-CHOP |
|---|---|---|
| Rate of Durable Response | 53.9 (44.5 to 63.4) | 67.6 (58.6 to 76.5) |
Proportion of subjects who achieved a CR with duration of at least 6 months
| percentage of participants | VR-CAP | R-CHOP |
|---|---|---|
| Rate of Durable Complete Response | 44.7 (35.3 to 54.1) | 47.3 (37.7 to 56.9) |
Kaplan-meier estimate of subsequent anti-lymphoma therapy at 1-year. Time to subsequent anti-lymphoma therapy was measured from the date of randomization to the start date of new treatment. Death due to disease progression prior to subsequent therapy was considered as an event. Otherwise, time to next anti-lymphoma treatment was censored at the date of death or the last date known to be alive.
| percentage of participants | VR-CAP | R-CHOP |
|---|---|---|
| Subsequent Anti-lymphoma Therapy Rate at 1-year | 71.1 (57.9 to 80.8) | 80.2 (68.8 to 87.9) |
Kaplan-meier estimate of progression-free survival at 1-year. Progression-free survival was defined as the interval between the date of randomization and the date of first documented evidence of disease progression or death.
| percentage of partipants | VR-CAP | R-CHOP |
|---|---|---|
| Progression-free Survival (PFS)Rate at 1-year | 78.9 (67.2 to 86.8) | 83.9 (72.7 to 90.8) |
Kaplan-meier estimate of overall survival at 1-year measured from date of randomization.
| percentage of partipants | VR-CAP | R-CHOP |
|---|---|---|
| Overall Survival Rate at 1-year | 94.1 (84.6 to 97.8) | 84.2 (73.2 to 91.0) |
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VR-CAP | — | 31/82 (37.8%) | 73/82 (89%) |
| R-CHOP | — | 27/79 (34.2%) | 72/79 (91.1%) |
| Event | VR-CAP | R-CHOP |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 7/82 | 7/79 |
| NeutropeniaBlood and lymphatic system disorders | 4/82 | 5/79 |
| PyrexiaGeneral disorders | 5/82 | 0/79 |
| PneumoniaInfections and infestations | 4/82 | 3/79 |
| Lung infectionInfections and infestations | 2/82 | 0/79 |
| DiarrhoeaGastrointestinal disorders | 2/82 | 0/79 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/82 | 0/79 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/82 | 0/79 |
| HypotensionVascular disorders | 2/82 | 0/79 |
| VertigoEar and labyrinth disorders | 2/82 | 0/79 |
| Event | VR-CAP | R-CHOP |
|---|---|---|
| ConstipationGastrointestinal disorders | 24/82 | 25/79 |
| Peripheral sensory neuropathyNervous system disorders | 23/82 | 15/79 |
| FatigueGeneral disorders | 21/82 | 11/79 |
| AnaemiaBlood and lymphatic system disorders | 19/82 | 17/79 |
| Oedema peripheralGeneral disorders | 14/82 | 5/79 |
| CoughRespiratory, thoracic and mediastinal disorders | 14/82 | 11/79 |
| Decreased appetiteMetabolism and nutrition disorders | 13/82 | 5/79 |
| DyspepsiaGastrointestinal disorders | 11/82 | 7/79 |
| Back painMusculoskeletal and connective tissue disorders | 11/82 | 6/79 |
| AlopeciaSkin and subcutaneous tissue disorders | 10/82 | 4/79 |
Intent to Treat, Randomized
| Age, Continuous(years) | VR-CAP | R-CHOP | Total |
|---|---|---|---|
| Mean | 56.5 ± 15.00 | 57.8 ± 13.83 | 57.2 ± 14.41 |
| Sex: Female, Male(Participants) | VR-CAP | R-CHOP | Total |
|---|---|---|---|
| Female | 43 | 33 | 76 |
| Male | 41 | 47 | 88 |
| Region of Enrollment(participants) | VR-CAP | R-CHOP | Total |
|---|---|---|---|
| Russian Federation | 22 | 14 | 36 |
| Turkey | 4 | 12 | 16 |
| Korea, Republic of | 6 | 6 | 12 |
| Malaysia | 5 | 3 | 8 |
| Canada | 3 | 3 | 6 |
| India | 2 | 4 | 6 |
| Brazil | 2 | 3 | 5 |
| Argentina | 2 | 1 | 3 |
| Singapore | 2 | 1 | 3 |
| Mexico | 0 | 1 | 1 |
| Germany | 13 | 8 | 21 |
| Portugal | 5 | 7 | 12 |
| Italy | 2 | 6 | 8 |
| Czech Republic | 3 | 4 | 7 |
| Spain | 5 | 2 | 7 |
| France | 2 | 4 | 6 |
| Belgium | 4 | 1 | 5 |
| Ireland | 2 | 0 | 2 |
The record gives a start of Jan 2010, a primary completion of Jun 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bortezomib
Lymphoma, Large B-Cell, Diffuse →
Millennium Pharmaceuticals, Inc. →